Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:1.14.16.2 (
tyrosine hydroxylase
)
14,760
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Phenylpropanolamine
(
PPA
) is an appetite suppressant. Repeated treatment with
PPA
can decrease food intake on initial days, but on subsequent days, food intake gradually returns to normal (tolerant effect). In an attempt to investigate the underlying mechanisms of
PPA
tolerance, the authors examined the roles of catecholamine (CAT) and hypothalamic neuropeptide Y (NPY) genome. Results revealed that pretreatment with either bupropion, a CAT transporter inhibitor, or a-methylparatyrosine, a
tyrosine hydroxylase
inhibitor, modulated the effect of
PPA
tolerance. Moreover, results also revealed that the alteration in NPY messenger RNA level coincided with the change of feeding behavior during
PPA
treatment and that infusions of NPY antisense oligonucleotide into the cerebroventricle abolished the effect of
PPA
tolerance. These findings suggest that cerebral CAT and hypothalamic NPY genome are involved in the development of tolerance to
PPA
-induced appetite suppression.
...
PMID:Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression. 1790 25
